View Financial HealthAB Science 배당 및 자사주 매입배당 기준 점검 0/6AB Science 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-6.2%자사주 매입 수익률총 주주 수익률-6.2%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew minor risk - Financial data availability Apr 28AB Science Announces New Publication Demonstrating Substantial Survival Benefits and Preserved Quality of Life with Masitinib in Amyotrophic Lateral Sclerosis PatientsApr 21AB Science Provides Update on Clinical Development ProgramApr 18New minor risk - Market cap size Mar 23AB Science SA Announces the Identification of A Plasma Biomarker That Indifies the Activity of Masitinib in Amyotrophic Lateral SclerosisFeb 25AB Science Sa Reports Fourth Consecutive Case of Response from Phase 1 Data for the Combination of Ab8939 with Venetoclax for the Treatment of Refractory or Relapsed Acute Myeloid LeukemiaJan 08AB Science S.A. has completed a Follow-on Equity Offering in the amount of €2.800001 million.Oct 17First half 2025 earnings released: €0.09 loss per share (vs €0.086 loss in 1H 2024) Oct 12New minor risk - Market cap size Aug 26New major risk - Share price stability Aug 13New minor risk - Shareholder dilution Aug 07AB Science S.A. announced that it expects to receive €2.550001 million in fundingAug 04+ 1 more updateAB Science SA Receives Regulatory Approval from European Countries to Initiate Third Stage of Phase I/II Study Combining Its Molecule AB8939 with Venetoclax for the Treatment of AMLJul 30AB Science Receives Approval from Several European Countries to Initiate the Confirmatory Phase 3 Study of Masitinib in ALSJul 24AB Science S.A. has completed a Follow-on Equity Offering in the amount of €1.925003 million.Jul 09AB Science SA Receives FDA and EMA Authorization for Confirmatory Phase 3 Trial in Metastatic Castrate-Resistant Prostate CancerJul 04New minor risk - Share price stability Jun 24AB Science SA Announces New Peer-Reviewed Data Provide Strong Evidence Supporting Masitinib Potential for the Treatment of Alzheimer's DiseaseJun 23Price target decreased by 26% to €2.54 Jun 17AB Science SA Announces EMA Approval of Masivet Shelf-Life Extension to 4 YearsJun 09New minor risk - Market cap size May 22AB Science S.A., Annual General Meeting, Jun 30, 2025May 22AB Science Receives Chinese Patent Protecting Masitinib in the Treatment of Covid-19 Until 2041, Adding One More Indication with Long Term Intellectual Property ProtectionMay 20AB Science SA Reports New Publication in the Scientific Journal PLOS OneMay 15AB Science S.A. Announces Positive Results from the Phase 2 Study of Masitinib in Covid-19May 14New major risk - Revenue and earnings growth May 13Full year 2024 earnings released: €0.15 loss per share (vs €0.24 loss in FY 2023) May 13AB Science S.A. to Present New Data from Masitinib Clinical Program in Als in Two Presentations At the 2025 ENCALS Annual MeetingMay 06New minor risk - Financial data availability Apr 28AB Science SA Receives Notice of Allowance for Unites States Patent Covering Masitinib Until 2040 in the Treatment of Sickle Cell DiseaseApr 15AB Science S.A. to Report First Half, 2025 Results on Sep 30, 2025Jan 30+ 1 more updateNew major risk - Revenue and earnings growth Jan 16AB Science Provides an Update on Its Ab8939 Program in Acute Myeloid LeukemiaDec 18New minor risk - Share price stability Dec 17AB Science Receives Notice of Allowance for European Patent Covering Masitinib Until 2040 in the Treatment of Sickle Cell DiseaseOct 29First half 2024 earnings released: €0.09 loss per share (vs €0.22 loss in 1H 2023) Oct 12AB Science Announces Positive Results of Its Phase 2 Study Evaluating Masitinib in Covid-19Jul 08Insufficient new directors Jul 01New minor risk - Market cap size Jun 03AB Science S.A., Annual General Meeting, Jun 26, 2024May 22Full year 2023 earnings released May 17New minor risk - Financial data availability Apr 28AB Science Announces Eligibility granted by Health Canada for Reconsideration Request for Masitinib in ALSApr 04Price target decreased by 27% to €6.90 Mar 15AB Science S.A. to Report First Half, 2024 Results on Sep 30, 2024Jan 30+ 1 more updateAB Science Receives Notice of Allowance for European Patent Covering masitinib Until 2036 in the Treatment of mastocytosisJan 16First half 2023 earnings released: €0.22 loss per share (vs €0.15 loss in 1H 2022) Oct 05New minor risk - Financial data availability Sep 17New minor risk - Financial data availability Sep 01New minor risk - Shareholder dilution Jul 31AB Science S.A. Receives Notice of Allowance for European Patent Covering Masitinib in the Treatment of Metastatic Castrate Refractory Prostate Cancer (mCRPC)Jun 29Full year 2022 earnings released: €0.29 loss per share (vs €0.30 loss in FY 2021) Apr 30AB Science S.A. to Report Fiscal Year 2022 Results on Apr 28, 2023Feb 08+ 1 more updateFirst half 2022 earnings released: EPS: €0 (vs €0.099 loss in 1H 2021) Oct 02First half 2021 earnings released: €0.099 loss per share (vs €0.23 loss in 1H 2020) Oct 04Price target increased to €23.11 Aug 16Full year 2020 earnings released May 03If You Had Bought AB Science (EPA:AB) Stock A Year Ago, You Could Pocket A 90% Gain TodayFeb 14What Kind Of Shareholders Hold The Majority In AB Science S.A.'s (EPA:AB) Shares?Dec 22New 90-day high: €14.34 Dec 16Our Take On AB Science's (EPA:AB) CEO SalaryNov 17First half earnings released Oct 01지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 AB 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: AB 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장AB Science 배당 수익률 vs 시장AB의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (AB)n/a시장 하위 25% (FR)2.0%시장 상위 25% (FR)5.5%업계 평균 (Pharmaceuticals)4.5%분석가 예측 (AB) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 AB 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 AB 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 AB 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: AB 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YFR 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/02 12:58종가2026/04/30 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스AB Science S.A.는 4명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Michael RyskinBofA Global ResearchSébastien MalafosseODDO BHF Corporate & MarketsJustin Steven SmithSociete Generale Cross Asset Research1명의 분석가 더 보기
AB Science Announces New Publication Demonstrating Substantial Survival Benefits and Preserved Quality of Life with Masitinib in Amyotrophic Lateral Sclerosis PatientsApr 21
AB Science SA Announces the Identification of A Plasma Biomarker That Indifies the Activity of Masitinib in Amyotrophic Lateral SclerosisFeb 25
AB Science Sa Reports Fourth Consecutive Case of Response from Phase 1 Data for the Combination of Ab8939 with Venetoclax for the Treatment of Refractory or Relapsed Acute Myeloid LeukemiaJan 08
AB Science S.A. announced that it expects to receive €2.550001 million in fundingAug 04+ 1 more update
AB Science SA Receives Regulatory Approval from European Countries to Initiate Third Stage of Phase I/II Study Combining Its Molecule AB8939 with Venetoclax for the Treatment of AMLJul 30
AB Science Receives Approval from Several European Countries to Initiate the Confirmatory Phase 3 Study of Masitinib in ALSJul 24
AB Science SA Receives FDA and EMA Authorization for Confirmatory Phase 3 Trial in Metastatic Castrate-Resistant Prostate CancerJul 04
AB Science SA Announces New Peer-Reviewed Data Provide Strong Evidence Supporting Masitinib Potential for the Treatment of Alzheimer's DiseaseJun 23
AB Science Receives Chinese Patent Protecting Masitinib in the Treatment of Covid-19 Until 2041, Adding One More Indication with Long Term Intellectual Property ProtectionMay 20
AB Science S.A. to Present New Data from Masitinib Clinical Program in Als in Two Presentations At the 2025 ENCALS Annual MeetingMay 06
AB Science SA Receives Notice of Allowance for Unites States Patent Covering Masitinib Until 2040 in the Treatment of Sickle Cell DiseaseApr 15
AB Science Receives Notice of Allowance for European Patent Covering Masitinib Until 2040 in the Treatment of Sickle Cell DiseaseOct 29
AB Science Announces Eligibility granted by Health Canada for Reconsideration Request for Masitinib in ALSApr 04
AB Science Receives Notice of Allowance for European Patent Covering masitinib Until 2036 in the Treatment of mastocytosisJan 16
AB Science S.A. Receives Notice of Allowance for European Patent Covering Masitinib in the Treatment of Metastatic Castrate Refractory Prostate Cancer (mCRPC)Jun 29
